Development of a Magnetic Resonance Imaging–Based Definition of Knee Osteoarthritis: Data From the Multicenter Osteoarthritis Study (2023) Liew JW, Rabasa G, LaValley M, Collins J, Stefanik J, Roemer F, Guermazi A, et al. Journal article Clinical Images: Increased bone metabolism in secondary hyperparathyroidism (2023) Valor-Mendez L, Atzinger A, Reis P, Manger B, Schett G Journal article Reset of inflammatory priming of joint tissue and reduction of the severity of arthritis flares by bromodomain inhibition (2023) Friščić J, Reinwald C, Böttcher M, Houtman M, Euler M, Chen X, Walker KI, et al. Journal article Concepts of entheseal pain (2023) De Lorenzis E, Natalello G, Simon D, Schett G, D'Agostino MA Journal article, Review article Short-term Safety of COVID-19 Vaccination in Systemic Sclerosis Patients: Report from a Global Patient-Reported E-survey (2022) Thakare D, Naveen R, Pauling J, Ahmed S, Wincup C, Del Papa N, Sambataro G, et al. Conference contribution Breakthrough Infections in COVID-19 Vaccinated Patients with Systemic Sclerosis: A Survival Analysis from a Multicenter International Patient-Reported Survey (2022) Ahmed S, Naveen R, Pauling J, Thakare D, Wincup C, Del Papa N, Sambataro G, et al. Conference contribution Vaccine Hesitancy Among Patients with Idiopathic Inflammatory Myopathies and Rheumatic Diseases in 2021-2022: A Comparative Analysis of COVID-19 Vaccination in Autoimmune Diseases Surveys (2022) Naveen R, Joshi M, Sen P, Agarwal V, Shinjo S, Kardes S, Lilleker JB, et al. Conference contribution COVID-19 Vaccination in Autoimmune Diseases Study: Vaccine Safety in Rheumatoid Arthritis (2022) Naveen R, Parodis I, Joshi M, Sen P, Kim M, Agarwal V, Kardes S, et al. Conference contribution COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey (2022) Dey M, Naveen R, Nikiphorou E, Sen P, Lilleker JB, Agarwal V, Kardes S, et al. Conference contribution Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study) (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, et al. Conference contribution